【摘要】 目的:初步研究192Ir(铱)高剂量率支气管腔内后装放射治疗(HDR-IBB)联合支气管动脉灌注化疗(BAI)和外照射(RT)治疗非小细胞肺癌(NSCLC)疗效的临床价值。方法:68例肺癌患者随机分成三联组和二联组进行治疗。结果:治疗后三联组卡氏评分提高16例,二联组卡氏评分提高6例。三联组卡氏评分提高经统计学分析,差异有显著性(P<0.05)。三联组近期有效率为90.3％,二联组近期有效率67.5％,两组差异有显著性(P<0.05)。三联组1年生存率为72.8％,而二联组1年生存率为44.8％,两组差异有显著性(P<0.05)。结论:BAI、RT及HDR-IBB三者联合治疗是NSCLC综合治疗的有效方法之一。更多还原

【Abstract】 Objective To study the clinical value of the treatment of HDR-IBB combined with BAI and RT. Methods Sixty-eight non-small cell lung cancer patients were divided randomizedly into two groups. Group I (BAI + RT group) was comprised of 37 patients treated with bronchial artery infusion chemotherapy(BAI) in combination with radiotherapy; Group Ⅱ (BAI + RT + IBB ) consisted of 31 patients treated with 192-Iridium high dose rate intrabronchial brachytherapy with bronchial artery infusion chemotherapy and radiotherapy. Patients were evaluated for KPS, objective response, one year survival rate as well as the acute side-effects. Re-Sults The improvement of karnofsky performance status (KPS) of the 68 patients was as follows: 6 patients obtained improvment in group I, 16 patients in group Ⅱ .There was statistical difference between the two groups (P < 0.05). Of the 68 patients in the two groups, 90.3 % ( 28/31) experienced objective response (CR + PR) in groupⅡ ,and 67.5%(25/37) in group I.There was significant difference after Ridit-test between the two groups(P < 0.01) .One year survival rate was 44.8% in group I and 72.8% in group Ⅱ. One year survival rate in groupⅡ was higher than that of group Ⅰ, there was statistical difference after log-rank test between the two groups (P < 0.05) . There was no statistical difference in acute side-effects between the two groups. Conclusion The protocol of 192-Iridium high dose rate intrabronchial brachytherapy (HDR-IBB) in combination with bronchial artery infusion (BAI) and radiotherapy (RT) is an effective and acceptable treatment for non-small cell lung cancer (NSCLC) .更多还原